Innovating Weight Loss with GLP-1 Activation
AllyMack is revolutionizing weight loss with our "Advanced GLP-1 Activator." Utilizing hemp-derived THCV, our needle-free, natural solution stimulates GLP-1 hormone production, offering an effective alternative to injectable drugs like Wegovy and Ozempic. Proven in human clinical trials, our easy-to-swallow capsule integrates seamlessly into daily health routines.
Why Invest in AllyMack?
- Market Potential: The GLP-1 market is expected to surpass $100 billion by 2030.
- Innovative Solution: Our product addresses the discomfort of injections with an oral alternative at much lower cost.
- Strategic Partnerships: Collaborations with industry leaders ensure a resilient supply chain.
- Gross margins above 60%
- Getting in early poses risks but huge potential rewards
- AllyMack will invest seed round capital into human clinical trials continuing where GW Pharmaceutical left off.
Join Our Pre-Seed Round
We are seeking pre-seed investors to propel our vision forward. This opportunity is exclusively for accredited investors or existing connections.
Contact Us
Interested in learning more? email reuben.gallegos@allymack.com
Legal Disclaimers
Disclaimer: Investing in early-stage companies involves significant risks, including illiquidity and the potential loss of capital. This solicitation is intended only for accredited investors as defined by the SEC or existing connections. Past performance is not indicative of future results. Perform your own due diligence and consider all risks before investing. AllyMack Inc. does not offer investment advice or guarantee any returns.
Join us at AllyMack Inc. and be part of a transformative journey to redefine health and wellness.
AllyMack Inc is a registered SD C Corporation.
